clinical trials

News

Boehringer drug scores in rare kidney disease FSGS

Boehringer's TRPC6 inhibitor apecotrep, formerly developed for COVID-19, has shown efficacy in the rare kidney disease FSGS in a phase 2 trial.

News

Roche claims midstage win for obesity injectable

Roche reports weight loss of up to 22.5% with its injectable GIP/GLP-1 agonist obesity drug, setting up phase 3, but will it be too late to the table?

News

Thomas Appio, Bausch Health's chief executive

Bausch Health hit as Xifaxan successor flunks trials

A hole has been blown in Bausch Health's late-stage pipeline, after a follow-up to its top-selling drug product Xifaxan failed two phase 3 trials.

News

Introducing the Sunday Times Tech 100: Life sciences part 1

The 2026 Sunday Times Tech 100 list includes 23 companies in the life sciences arena, and in this article we focus on five in the software category.

News

Sanofi plans amlitelimab dermatitis filing after new readout

Sanofi has said it will press ahead with regulatory filings for atopic dermatitis candidate amlitelimab, despite mixed data in phase 3.

News

Ovarian cancer data restores faith in Corcept's relacorilant

After Corcept's setback with relacorilant in Cushing syndrome last month, the company has bounced back with strong survival data in ovarian cancer.

Boehringer drug scores in rare kidney disease FSGS

Roche claims midstage win for obesity injectable

Bausch Health hit as Xifaxan successor flunks trials

Introducing the Sunday Times Tech 100: Life sciences part 1

Sanofi plans amlitelimab dermatitis filing after new readout

Ovarian cancer data restores faith in Corcept's relacorilant

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

clinical trials

Editor's Picks